MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)

A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study B

The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with Human Immunodeficiency Virus (HIV).

Inclusion Criteria:

• Patient is at least 18 years of age
• Patient is human immunodeficiency virus (HIV) positive
• Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) <50 copies/milliliter (mL) for at least 3 months while on a KALETRA based regimen
• Patient has been on a KALETRA based regimen for at least 3 months without a change in background antiretroviral therapy
• Patient has no documentation of HIV RNA >50 copies/mL for at least 3 months while on the KALETRA based regimen

Exclusion Criteria:

• Patient is or plans to become pregnant, or is nursing a child
• Patient plans to donate eggs or impregnate/donate sperm
• Patient is receiving Stavudine (d4T) as a component of the background antiretroviral therapy
• Patient is currently receiving a second protease inhibitor in addition to KALETRA
• Patient is currently receiving, or has received in the past twelve weeks, treatment for the management of elevated lipids
• Patient has used another experimental HIV-integrase inhibitor
• Patient has a current (active) diagnosis of acute hepatitis due to any cause